Clinical epidemiology of infectious disease among patients with chronic kidney disease

Junichi Ishigami, Kunihiro Matsushita, Junichi Ishigami, Kunihiro Matsushita

Abstract

Infectious disease is recognized as an important complication among patients with end-stage renal disease, contributing to excess morbidity and health care costs. However, recent epidemiological studies have revealed that even mild to moderate stages of chronic kidney disease (CKD) substantially increase risk of infection. Regarding underlying mechanisms, evidence suggests various aspects of altered immune response in patients with CKD including impaired function of T cells, B cells and neutrophil. Multiple conditions surrounding CKD, such as older age, diabetes, and cardiovascular disease are important contributors in the increased susceptibility to infection in this population. In addition, several mechanisms impairing immune function have been hypothesized including accumulated uremic toxins, increased oxidative stress, endothelial dysfunction, low-grade inflammation, and mineral and bone disorders. In terms of prevention strategies, influenza and pneumococcal vaccines are most feasible and important. Nevertheless, the extent of vaccine utilization in CKD has not been well documented. In addition, antibody response to vaccination may be reduced in CKD patients, and thus a vaccine delivery strategy (e.g., dose and frequency) may need to be optimized among patients with CKD. Through this review, we demonstrate that infection is a major but underrecognized complication of CKD. As CKD is recognized as a serious public health issue, dedicated research is needed to better characterize the burden of infectious disease associated with CKD, understand the pathophysiology of infection in patients with CKD, and develop effective strategies to prevent infection and its sequela in this high risk population.

Keywords: Bloodstream infections; Chronic kidney disease; Infections; Influenza vaccination; Pneumococcal vaccination; Pneumonia; Renal failure.

Conflict of interest statement

Conflict of interest

The author reports no conflicts of interest in this work.

Human and animal rights statement

This work does not include any analysis involving human or animal subjects.

Informed consent

There is no involvement of human subjects in this work.

Figures

Fig. 1
Fig. 1
Adjusted hazard ratio of hospitalization with infection by eGFR and ACR categories. GFR glomerular filtration rate, ACR albumin-to-creatinine ratio. Green: low risk; yellow: moderately increased risk; orange: high risk; red, very high risk. For each category, hazard ratio and its 95% confidence interval were presented in the first row, and n = denotes number of events and number of individuals in the second row. The model was adjusted for age, race, sex, body mass index, smoking status, alcohol consumption, education level, use of antineoplastic agents and steroids, hypertension, diabetes, history of cancer, chronic obstructive pulmonary disease, prior heart failure, prior coronary disease, and prior stroke. Reprinted from reference 15 with permission
Fig. 2
Fig. 2
Potential mechanisms increasing infection in chronic kidney disease. CKD chronic kidney disease, CVD cardiovascular disease

References

    1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–272.
    1. United States Renal Data System . 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015.
    1. Barzilay JI, Fitzpatrick AL, Luchsinger J, Yasar S, Bernick C, Jenny NS, et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis. 2008;52(2):216–226.
    1. Daya NR, Voskertchian A, Schneider AL, Ballew S, McAdams DeMarco M, Coresh J, et al. Kidney function and fracture risk: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2016;67(2):218–226.
    1. Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K. Chronic kidney disease and risk for gastrointestinal bleeding in the community: the Atherosclerosis Risk in Communities (ARIC) Study. Clin J Am Soc Nephrol. 2016;11(10):1735–1743.
    1. Saran R, Robinson B, Abbott KC, Agodoa LY, Ayanian J, Bragg-Gresham J, US Renal Data System 2016 Annual Data Report et al. Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69(3S1):A7–A8.
    1. James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR, et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168(21):2333–2339.
    1. James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 2009;54(1):24–32.
    1. Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and risk for hospitalization with infection: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2016
    1. Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356–363.
    1. McDonald HI, Thomas SL, Millett ER, Nitsch D. CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records. Am J Kidney Dis. 2015;66(1):60–68.
    1. Xu H, Gasparini A, Ishigami J, Mzayen K, Su G, Barany P, et al. eGFR and the risk of community-acquired infections. Clin J Am Soc Nephrol. 2017;12(9):1399–1408.
    1. Yates C, May K, Hale T, Allard B, Rowlings N, Freeman A, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907–1909.
    1. Berns JS. Infection with antimicrobial-resistant microorganisms in dialysis patients. Semin Dial. 2003;16(1):30–37.
    1. Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and risk for hospitalization with infection: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2017;69(6):752–761.
    1. Wang HE, Gamboa C, Warnock DG, Muntner P. Chronic kidney disease and risk of death from infection. Am J Nephrol. 2011;34(4):330–336.
    1. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV., Jr Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol. 2015
    1. Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, et al. Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT) Am J Kidney Dis. 2015
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
    1. Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006;118(1):83–91.
    1. Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(1):204–212.
    1. Anding K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant. 2003;18(10):2067–2073.
    1. Gollapudi P, Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol. 2010;31(3):247–254.
    1. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2431–2438.
    1. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958–965.
    1. Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol. 2009;9(1):57–62.
    1. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–1065.
    1. Cheikh Hassan HI, Tang M, Djurdjev O, Langsford D, Sood MM, Levin A. Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. Kidney Int. 2016;90(4):897–904.
    1. Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol. 2003;14(7):1863–1870.
    1. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014;25(9):1897–1907.
    1. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 2007;22(2):592–596.
    1. Kim HY, Yoo TH, Hwang Y, Lee GH, Kim B, Jang J, et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD) Sci Rep. 2017;7(1):3057.
    1. Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol. 2013;24(12):1981–1994.
    1. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010;25(11):3693–3700.
    1. Banerjee T, Meyer TW, Shafi T, Hostetter TH, Melamed M, Zhu Y, et al. Free and total p-cresol sulfate levels and infectious hospitalizations in hemodialysis patients in CHOICE and HEMO. Medicine. 2017;96(6):e5799.
    1. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584.
    1. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63.
    1. Zeisel SH, Warrier M. Trimethylamine N-Oxide, the microbiome, and heart and kidney disease. Ann Rev Nutr. 2017;37:157–181.
    1. Sack MN, Fyhrquist FY, Saijonmaa OJ, Fuster V, Kovacic JC. Basic biology of oxidative stress and the cardiovascular system: Part 1 of a 3-Part series. J Am Coll Cardiol. 2017;70(2):196–211.
    1. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469–473.
    1. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009;22(6):636–643.
    1. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65(3):1009–1016.
    1. Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int. 2007;71(2):167–172.
    1. Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun. 2015;57:1–13.
    1. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012;18(8):1217–1223.
    1. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84(3):869–901.
    1. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004;43(2):244–253.
    1. Salmon AH, Ferguson JK, Burford JL, Gevorgyan H, Nakano D, Harper SJ, et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol. 2012;23(8):1339–1350.
    1. Seliger SL, Salimi S, Pierre V, Giffuni J, Katzel L, Parsa A. Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults. BMC Nephrol. 2016;17(1):82.
    1. Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, et al. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study) Am J Cardiol. 2004;94(3):294–299.
    1. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120(6):502–509.
    1. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41(6):1212–1218.
    1. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938–1946.
    1. Wang HE, Shapiro NI, Safford MM, Griffin R, Judd S, Rodgers JB, et al. High-sensitivity C-reactive protein and risk of sepsis. PloS One. 2013;8(7):e69232.
    1. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Inflammatory and endothelial activation biomarkers and risk of sepsis: a nested case-control study. J Crit Care. 2013;28(5):549–555.
    1. Yende S, Tuomanen EI, Wunderink R, Kanaya A, Newman AB, Harris T, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med. 2005;172(11):1440–1446.
    1. Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006;70(2):371–376.
    1. Bacchetta J, Salusky IB, Hewison M. Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? Pediatr Nephrol. 2013;28(4):577–582.
    1. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol. 2016;27(1):227–237.
    1. Nowak KL, Bartz TM, Dalrymple L, de Boer IH, Kestenbaum B, Shlipak MG, et al. Fibroblast growth factor 23 and the risk of infection-related hospitalization in older adults. J Am Soc Nephrol. 2016
    1. Ishigami J, Jaar BG, Rebholz CM, Grams ME, Michos ED, Wolf M, et al. Biomarkers of mineral and bone metabolism and 20-year risk for hospitalization with infection: the ARIC study. J Clin Endocrinol Metab. 2017
    1. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.
    1. European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe. . Accessed 30 Jan 2018.
    1. World Health Organization. Influenza vaccine use. . Accessed 30 Jan 2018.
    1. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322–1332.
    1. Grijalva CG, Zhu Y, Williams DJ, Self WH, Ampofo K, Pavia AT, et al. Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. JAMA. 2015;314(14):1488–1497.
    1. Hak E, Nordin J, Wei F, Mullooly J, Poblete S, Strikas R, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35(4):370–377.
    1. Gilbertson DT, Unruh M, McBean AM, Kausz AT, Snyder JJ, Collins AJ. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int. 2003;63(2):738–743.
    1. McGrath LJ, Kshirsagar AV, Cole SR, Wang L, Weber DJ, Sturmer T, et al. Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med. 2012;172(7):548–554.
    1. Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, et al. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PloS One. 2013;8(3):e58317.
    1. Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, et al. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Vaccine. 2012;30(33):5009–5018.
    1. Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, et al. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Vaccine. 2012;30(6):1108–1114.
    1. Birdwell KA, Ikizler MR, Sannella EC, Wang L, Byrne DW, Ikizler TA, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009;54(1):112–121.
    1. Crespo M, Collado S, Mir M, Cao H, Barbosa F, Serra C, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol. 2011;6(9):2208–2214.
    1. Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis. 2009;54(1):77–85.
    1. Ortbals DW, Marks ES, Liebhaber H. Influenza immunization in patients with chronic renal disease. JAMA. 1978;239(24):2562–2565.
    1. Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15(3):293–300.
    1. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645.
    1. Noh JY, Song JY, Choi WS, Lee J, Seo YB, Kwon YJ, et al. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines. Hum Vaccin Immunother. 2016;12(11):2902–2908.
    1. Broeders NE, Hombrouck A, Lemy A, Wissing KM, Racape J, Gastaldello K, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol. 2011;6(11):2573–2578.
    1. Chang YT, Wang JR, Lin MT, Wu CJ, Tsai MS, Wen-Chi CL, et al. Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients—an 18-week, open-label trial. Sci Rep. 2016;6:20725.
    1. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125.
    1. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. The Cochrane Database Syst Rev. 2013;1:CD000422.
    1. Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis. 2012;60(6):959–965.
    1. Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transpl. 2011;26(9):2934–2939.
    1. Linnemann CC, Jr, First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med. 1986;146(8):1554–1556.
    1. Fuchshuber A, Kuhnemund O, Keuth B, Lutticken R, Michalk D, Querfeld U. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transpl. 1996;11(3):468–473.
    1. Nikoskelainen J, Koskela M, Forsstrom J, Kasanen A, Leinonen M. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int. 1985;28(4):672–677.
    1. Mitra S, Stein GE, Bhupalam S, Havlichek DH. Immunogenicity of 13-valent conjugate pneumococcal vaccine in patients 50 years and older with end-stage renal disease and on dialysis. Clin Vaccine Immunol. 2016;23(11):884–887.
    1. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187(10):1639–1645.
    1. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients–three year follow-up of a randomized trial. Am J Transplant. 2007;7(3):633–638.
    1. Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PloS One. 2012;7(9):e46133.
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
    1. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208.
    1. World Health Organization. Department of Communicable Disease, Surveillance and Response. Prevention ofhospital-acquiredinfections. . Accessed 05 May 2018.
    1. Flodgren G, Conterno LO, Mayhew A, Omar O, Pereira CR, Shepperd S. Interventions to improve professional adherence to guidelines for prevention of device-related infections. Cochrane Database Syst Rev. 2013
    1. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. J Am Med Assoc. 2005;293(10):1223–1238.
    1. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm. 2013;70(3):195–283.
    1. American Dental Association. Antibiotic Prophylaxis Prior to Dental Procedures. Available: . Accessed 05 May 2018.
    1. Calfee DP. Multidrug-resistant organisms in dialysis patients. Semin Dial. 2013;26(4):447–456.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe